Surveyed nephrologists by REACH Market Research report that Filspari and Tarpeyo are already being prescribed to as many as 1 in 5 IgAN patients. NEWTON, Mass., July 27, 2023 /PRNewswire/ — IgA nephropathy (IgAN) is an autoimmune glomerular disease and leading cause of chronic kidney…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.